Chunk #23 — Building and Supporting the REDCap Consortium: A Phased Approach — Phase 4: Creating a Broader National Presence (~ 50 sites; ~ 2008–2009) — Benefits:
The uptake and use of REDCap at many institutions provided great scientific and collaborative return on investment. During 2008 and 2009, our earliest phase of formally tracking return on investment for REDCap support at Vanderbilt, our local research teams cited REDCap’s value in securing 23 new funded/awarded projects across numerous biomedical research areas (e.g., clinical pharmacology, vaccine and treatment evaluation, epilepsy monitoring, mental health, emergency department heart failure risk stratification, genetic markers and predictive risk modeling, nutrition, pediatric obesity, asthma, cystic fibrosis). We were also encouraged by similar success metrics and diverse use cases reported in ad hoc fashion by other Consortium REDCap administrators. By using REDCap, many research users across the U.S. were able to work on a local data management platform also used locally by peers at other institutions, which promoted resource sharing while reducing training costs. Institutional Review Boards (IRBs) and Privacy Offices became aware of the platform and were supportive of our goal to provide research teams with “an easy way to do the right thing” regarding data collection and management. Research users at local institutions
